787 Tivuron Project: An International Multicenter Prospective Cohort Study Evaluating the Gastrointestinal Symptoms and Complications of Covid-19 in Hospitalized Patients

The Liver and COVID‐19 in Mexico

“…After excluding patients with history of chronic liver disease, abnormal LFT on admission were independently associated with death and severe COVID‐19, both adjusted by age, gender, diabetes, pneumonia, and body mass index >30. Similar results have shown in recent prospective multicenter international cohort among 829 hospitalized patients (203 from Mexico), in whom hypertransaminasemia was present in 267 patients (32.3%) and liver injury during hospitalization was associated with a higher hospital stay (>10 days) and worst outcome 5 . Further studies in our population have shown consistently that abnormal LFT, in particular alanine aminotransferase and aspartate aminotransferase, were associated with a higher in‐hospital mortality risk (Table 1).…”

“…Similar results have shown in recent prospective multicenter international cohort among 829 hospitalized patients (203 from Mexico), in whom hypertransaminasemia was present in 267 patients (32.3%) and liver injury during hospitalization was associated with a higher hospital stay (>10 days) and worst outcome. 5 Further studies in our population have shown consistently that abnormal LFT, in particular alanine aminotransferase and aspartate aminotransferase, were associated with a higher in-hospital mortality risk (Table 1). 10,11 PreeXisTinG liver Disease anD COviD-19…”

“…1). 4,5 Immediately, medical associations dedicated to gastroenterology and hepatology in Mexico issued recommendations and guidelines for the identification, management, and treatment of patients with liver manifestations associated with SARS-CoV-2, as well as for patients with pre-existing liver disease and liver transplant. 7,8 Also, the groups dedicated to the research of liver diseases in Mexico in collaboration with national and international partners undertook the task of describing the first series of cases, risk factors, and mortality associated with COVID-19 in Mexicans (Table 1).…”

Impacto de COVID-19 en enfermedad hepatica pre-existente

“…After excluding patients with a history of chronic liver disease, abnormal LFT on admission were independently associated with death and severe COVID-19, both adjusted by age, gender, diabetes, pneumonia and body mass index > 30. Similar results were shown in a recent prospective multicenter international cohort among 829 hospitalized patients (203 from Mexico), in whom hypertransaminasemia was present in 267 patients (32.3%) and liver injury during hospitalization was associated with a higher hospital stay (> 10 days) and worse outcome 6 .…”

“…Gastrointestinal and liver manifestations were reported in up to 40% of Mexican patients infected by SARS-CoV-2 since the beginning of the pandemic. Medical associations related to gastroenterology and hepatology issued guidelines for the identification, management and treatment of patients with COVID-19 hepatic manifestations, as well as for patients with pre-existing liver disease and liver transplant 5,6 .…”